National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 1416115

History of Changes from the VAERS Wayback Machine

First Appeared on 7/23/2021

VAERS ID: 1416115
VAERS Form:2
Age:30.0
Sex:Female
Location:Foreign
Vaccinated:2021-06-04
Onset:2021-06-04
Submitted:0000-00-00
Entered:2021-06-21
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH EY5454 / UNK - / -

Administered by: Other      Purchased by: ??
Symptoms: Fatigue

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': GBPFIZER INC2021657544

Write-up: Fatigue; regulatory authority This is a Non-Interventional Study report from a contactable consumer. This is a report received from the regulatory authority. Regulatory authority report number GB-MHRA-YCVM-202105302033418200-W0D1R, Safety Report Unique Identifier GB-MHRA-ADR 25422787. A 30-year-old female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 04Jun2021 (Lot Number: EY5454) (at the age of 30-year-old) as single dose for COVID-19 immunisation. The patient was not pregnant and not currently breastfeeding, last menstrual period was 23May2021. The patient medical history and concomitant medications were not reported. The patient experienced fatigue on 04Jun2021. The event was serious, medically significant. The patient outcome of the event was recovering. Additional Information: the patient has not had symptoms associated with COVID-19. Not had a COVID-19 test. The patient was not enrolled in clinical trial. The reporter''s assessment of the causal relationship of the event with the suspect product was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality assessment. No follow-up attempts are possible. No further information is expected.; Sender''s Comments: Based on the current available information and the consistency with the known safety profile of the suspect product BNT162B2, there is a reasonable possibility that event fatigue was related to suspect drug.

New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1416115&WAYBACKHISTORY=ON


Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166